摘要
siponimod是由诺华制药公司研发的新一代1-磷酸鞘氨醇受体调节剂,2019年3月获得美国食品和药物管理局批准,用于治疗复发型多发性硬化症,包括临床孤立综合征、复发缓解型疾病和继发进展型疾病。临床试验证实siponimod能有效降低继发进展型多发性硬化症患者的残疾进展,常见不良反应包括头痛、高血压和鼻咽炎等。
Siponimod is a new sphingosine 1-phosphate receptor modulator, developed by Novartis. In March 2019,siponimod was approved by the U.S. Food and Drug Adiministration for the treatment of adult patients with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease. Siponimod was clinically demonstrated to be a useful treatment for secondary progressive multiple sclerosis because it reduced the risk of disability progression. The most common adverse reactions are headache, hypertension, nasopharyngitis, and so on.
作者
张爱林
毕恒泰
高清
ZHANG Ai-lin;BI Heng-tai;GAO Qing(Department of Pharmacy,the People's Hospital of Linqu,Lirufu SHANDONG 262600,China;Department of Pharmacy,the People's Hospital of Weifang,Weifang SHANDONG 261000,China)
出处
《中国新药与临床杂志》
CAS
CSCD
北大核心
2020年第5期273-276,共4页
Chinese Journal of New Drugs and Clinical Remedies
